Antimicrobial agents are the cornerstone of modern medicine, saving countless lives and making many common surgeries possible. However, the problem of antimicrobial resistance is becoming more and more serious and has become a major challenge to the prevention and treatment of bacterial infections. At present, some important pathogenic bacteria have developed resistance to almost all existing antibacterial drugs, rendering the clinical treatment extremely difficult. Should this situation not be effectively under control, humans are likely to enter the "post-antibiotic era". Meanwhile, along with the progress of medical science, new types of infections e.g. biofilm infection associated with implanted medical devices have been emerging, which are lack of effective therapies. The development of high-throughput gene sequencing technology and microbiomics has offered better understanding and new mechanism for the treatment of diseases associated with bacterial metabolism and microbiome, such as hepatic encephalopathy, diarrhea-predominant irritable bowel syndrome, inflammatory bowel disease and NASH. TenNor focuses on the research and development of new drugs in the field of bacterial infections and metabolic related diseases. TenNor has developed a highly differentiated innovation pipeline with global patent protection, aiming at the “first-in-class” or “best-in-class” new drug therapies to address the unmet needs in the related therapeutic fields.